JP Morgan Chase’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$65M Sell
305,100
-600
-0.2% -$133K ﹤0.01% 1224
2025
Q4
$69.8M Sell
305,700
-55,400
-15% -$12.6M ﹤0.01% 1149
2025
Q3
$83.6M Buy
361,100
+44,600
+14% +$9.08M 0.01% 1088
2025
Q2
$58.7M Sell
316,500
-197,600
-38% -$36.7M ﹤0.01% 1238
2025
Q1
$108M Sell
514,100
-369,700
-42% -$71.9M 0.01% 891
2024
Q4
$157M Buy
883,800
+87,700
+11% +$16.1M 0.01% 746
2024
Q3
$157M Buy
796,100
+483,800
+155% +$90.3M 0.01% 771
2024
Q2
$53.6M Sell
312,300
-147,800
-32% -$24.5M ﹤0.01% 1212
2024
Q1
$83.8M Buy
460,100
+249,200
+118% +$42.9M 0.01% 1016
2023
Q4
$32.7M Buy
210,900
+141,800
+205% +$20.7M ﹤0.01% 1476
2023
Q3
$10.3M Hold
69,100
﹤0.01% 2218
2023
Q2
$9.31M Sell
69,100
-250,600
-78% -$36.7M ﹤0.01% 2344
2023
Q1
$51M Sell
319,700
-759,900
-70% -$116M 0.01% 1096
2022
Q4
$174M Buy
1,079,600
+203,800
+23% +$31.2M 0.02% 558
2022
Q3
$118M Buy
875,800
+303,900
+53% +$43.6M 0.02% 659
2022
Q2
$87.6M Buy
571,900
+19,700
+4% +$3.01M 0.01% 795
2022
Q1
$89.5M Buy
552,200
+87,500
+19% +$12.7M 0.01% 884
2021
Q4
$62.9M Buy
464,700
+155,900
+50% +$18.4M 0.01% 1092
2021
Q3
$33.3M Buy
308,800
+208,000
+206% +$23.8M ﹤0.01% 1404
2021
Q2
$11.4M Buy
100,800
+82,700
+457% +$9.31M ﹤0.01% 2320
2021
Q1
$1.96M Sell
18,100
-237,700
-93% -$25.4M ﹤0.01% 3743
2020
Q4
$27.4M Buy
255,800
+40,500
+19% +$3.89M ﹤0.01% 1403
2020
Q3
$18.7M Sell
215,300
-115,000
-35% -$10.8M ﹤0.01% 1539
2020
Q2
$32.4M Sell
330,300
-120,500
-27% -$10.6M 0.01% 1081
2020
Q1
$34.3M Buy
450,800
+219,200
+95% +$18.7M 0.01% 961
2019
Q4
$20.5M Sell
231,600
-180,900
-44% -$15M ﹤0.01% 1574
2019
Q3
$31.2M Buy
412,500
+12,500
+3% +$857K 0.01% 1252
2019
Q2
$28M Buy
400,000
+4,600
+1% +$362K 0.01% 1326
2019
Q1
$31.9M Buy
395,400
+141,100
+55% +$11.5M 0.01% 1215
2018
Q4
$23.4M Hold
254,300
0.01% 1367
2018
Q3
$24.1M Buy
254,300
+109,600
+76% +$10.4M ﹤0.01% 1521
2018
Q2
$13.4M Sell
144,700
-95,000
-40% -$9.28M ﹤0.01% 1907
2018
Q1
$22.7M Sell
239,700
-527,400
-69% -$57.9M ﹤0.01% 1423
2017
Q4
$74.2M Buy
767,100
+210,300
+38% +$19.8M 0.02% 788
2017
Q3
$49.5M Buy
556,800
+33,800
+6% +$2.57M 0.01% 934
2017
Q2
$37.9M Sell
523,000
-244,950
-32% -$16.5M 0.01% 1064
2017
Q1
$50M Buy
767,950
+27,550
+4% +$1.73M 0.01% 948
2016
Q4
$46.4M Buy
740,400
+592,586
+401% +$36.2M 0.01% 937
2016
Q3
$9.32M Sell
147,814
-8,430,000
-98% -$546M ﹤0.01% 1844
2016
Q2
$531M Buy
8,577,814
+8,553,814
+35,641% +$521M 0.13% 176
2016
Q1
$1.37M Sell
24,000
-190,700
-89% -$10.6M ﹤0.01% 2905
2015
Q4
$12.7M Buy
214,700
+139,700
+186% +$8.05M ﹤0.01% 1657
2015
Q3
$4.08M Buy
75,000
+48,800
+186% +$3.18M ﹤0.01% 2349
2015
Q2
$1.76M Sell
26,200
-38,800
-60% -$2.53M ﹤0.01% 2975
2015
Q1
$3.81M Sell
65,000
-233,500
-78% -$14.1M ﹤0.01% 2526
2014
Q4
$19.5M Buy
298,500
+243,500
+443% +$15.4M ﹤0.01% 1483
2014
Q3
$3.18M Buy
+55,000
New +$3.05M ﹤0.01% 2635
2014
Q1
Sell
-30,700
Closed -$1.62M 3550
2013
Q4
$1.62M Buy
30,700
+5,700
+23% +$280K ﹤0.01% 2885
2013
Q3
$1.12M Buy
+25,000
New +$1.11M ﹤0.01% 3197

Other funds holding ABBV

JP Morgan Chase's ABBV Position: Q1 2026 in Review

JP Morgan Chase increased its AbbVie (ABBV) stake by 8.3% in Q1 2026, buying an estimated $965M and bringing the position to 56,741,691 shares worth $12.1B. The position accounts for 0.78% of the portfolio, ranked #19.

JP Morgan Chase first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.1B in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • JP Morgan Chase held 56,741,691 shares of AbbVie worth $12.1B as of Q1 2026.
  • JP Morgan Chase bought 4,348,368 AbbVie shares in Q1 2026, an estimated $965M.
  • AbbVie made up 0.78% of JP Morgan Chase's portfolio in Q1 2026, its #19 holding.
  • JP Morgan Chase first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's AbbVie position peaked at $13.1B in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.